Colorectal cancer risk remains despite modern treatment for ulcerative colitis

Patients with the inflammatory bowel disease ulcerative colitis have a higher risk of dying from colorectal cancer, despite modern therapy, even though the risk has declined in recent years. This is according to a new study published in the scientific journal The Lancet by a team of Swedish and Danish researchers.

Previous research has shown that patients with ulcerative colitis have an increased risk of colorectal cancer. Screening recommendations are therefore in place for this patient group. But to what extent have new therapeutic methods helped to reduce this risk? This much-debated question has now found new answers. A large study involving 96,000 patients diagnosed with ulcerative colitis between the years 1969 and 2017 has now shown that these patients run a higher risk of developing and dying of colorectal cancer.

“The risk of colorectal cancer has dropped substantially over the past 30 years, but in spite of this patients who have had access to modern treatments for ulcerative colitis and screening for colorectal cancer still have a significantly elevated risk,” says Ola Olén, senior researcher at the Department of Medicine in Solna at Karolinska Institutet in Sweden.

Seen over the entire study period (1969 – 2017) the chances of a patient with ulcerative colitis being diagnosed with colorectal cancer were 66 percent higher than the control group, with the corresponding mortality rate 59 percent higher. For the latest five-year period only, however, these figures were, respectively, 38 percent and 25 percent.

This study differs from previous ones in that it factored in both the tumour stage when the cancer risk was assessed and the mortality rates, which the researchers included to ensure that the risks were not being over-estimated. The reason for examining mortality from colorectal cancer and not only incidence for this cancer is that regular endoscopic screening might detect relatively early forms of colorectal cancer that would otherwise go undetected.

“An important result of the study is that the risks are indeed elevated but there are major differences from one patient group to another,” says Olén.

At particularly high risk of developing colorectal cancer are the patients with extensive colitis, primary sclerosing cholangitis (a liver complication sometimes seen in ulcerative colitis), heredity for colorectal cancer susceptibility or childhood onset ulcerative colitis. 

According to co-author and Professor Jonas F Ludvigsson, the study indicates a need to develop the care provided for these patients even further.

“Our study shows that screening and treatment of these patients can likely be further improved, since patients with ulcerative colitis are still more likely to die of colon cancer,” he says.

Funding for this project was provided, in part, by the Swedish Medical Society, Mag-tarmfonden, Karolinska Institutet Foundations, the Strategic Research Area Epidemiology programme at Karolinska Institutet, the Swedish Cancer Society, the Stockholm County Council, the Swedish Research Council, the Swedish Foundation for Strategic Research, the FORTE Foundation, the Swedish Cancer Foundation and the Independent Research Fund Denmark.

Publication: “Colorectal cancer in ulcerative colitis: A Scandinavian population-based cohort study”. Ola Olén, Rune Erichsen, Michael C Sachs, Lars Pedersen, Jonas Halfvarson, Johan Askling, Anders Ekbom, Henrik Toft Sørensen, Jonas F Ludvigsson, The Lancet, online January, 2020.

For more information, please contact:
Ola Olén, senior researcher
Department of Medicine, Solna, Karolinska Institutet
Phone: +46 (0)70-327 0974
Email: ola.olen@ki.se

Contact the Press Office and download photo: ki.se/pressroom

Karolinska Institutet is one of the world’s leading medical universities. Our vision is to advance knowledge about life and strive towards better health for all. Karolinska Institutet accounts for the single largest share of all academic medical research conducted in Sweden and offers the country’s broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine.

Tags: